UniPharma , Ltd. EBIT

UniPharma , Ltd. (6621.TWO) currently reports a EBIT of $-84M as of June 2026. That compares with $-48M in the prior-year period — down 73.7% year over year. That is below the sector sector average of $2.6T. Use the charts on this page to explore UniPharma , Ltd.'s EBIT history and peer comparisons.

UniPharma , Ltd.'s EBIT decreased from $-48M to $-84M — a 73.7% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

UniPharma , Ltd.'s EBIT of $-84M is lower than the its sector sector average of $2.6T. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

UniPharma , Ltd. reported $-84M in EBIT as of June 2026. That compares with $-48M in the prior-year period — down 73.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-84M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $2.6T. From there, open related valuation or income-statement pages for UniPharma , Ltd., and consider following 6621.TWO for alerts when major investors trade the stock.